Physician profile
Michelle Squires
NPI 1013615566
$1,297.26
in general payments reported to CMS, 2019-2025
21 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $771 · 2024: $374 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,297.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $161.80 | 2023-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $150.75 | 2023-2024 | Caplyta |
| Abbvie INC. | $146.40 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $123.18 | 2023-2024 | Breztri, Farxiga, Flumist Quadrivalent |
| Otsuka America Pharmaceutical, INC. | $85.50 | 2023 | Nuedexta, Abilify Maintena, Rexulti |
| Glaxosmithkline, LLC. | $85.16 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Aimmune Therapeutics, INC. | $67.09 | 2024-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $64.69 | 2023 | |
| Antares Pharma, INC. | $61.68 | 2023-2024 | Xyosted, Nocdurna, Tlando |
| Astellas Pharma US INC | $59.83 | 2023-2024 | Veozah |
| Lilly USA, LLC | $54.25 | 2023-2024 | Mounjaro, Zepbound |
| Dexcom, INC. | $38.54 | 2023 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $30.42 | 2025 | Symbravo |
| Sumitomo Pharma America, INC. | $29.77 | 2024 | Gemtesa |
| Amarin Pharma, INC. | $24.77 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Halozyme INC | $20.54 | 2023 | |
| Novo Nordisk INC | $19.35 | 2023 | |
| Janssen Pharmaceuticals, INC | $18.93 | 2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.89 | 2025 | Xifaxan |
| Azurity Pharmaceuticals, INC. | $18.68 | 2024 | Horizant |
| Exact Sciences Corporation | $17.04 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Squires listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.